|Bid||80.02 x 800|
|Ask||80.04 x 1100|
|Day's Range||79.24 - 80.25|
|52 Week Range||69.10 - 95.19|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||45.35|
|Earnings Date||Feb 04, 2021|
|Forward Dividend & Yield||0.98 (1.19%)|
|Ex-Dividend Date||Dec 03, 2020|
|1y Target Est||93.56|
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information.